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Case Report 
Liver Transplantation for Combined Hepatocellular
Cholangiocarcinoma
Albert Chi-Yan Chan, Chung Mau Lo, Irene Oi-Lin Ng and Sheung Tat Fan, Department of Surgery, 
The University of Hong Kong, Hong Kong SAR.
Combined hepatocellular cholangiocarcinoma (cHCC-CC) is an uncommon histological variant of pri-
mary liver cancer. This combined type of tumour lesion follows an aggressive clinical course with an
unfavourable prognosis. Although the role of orthotopic liver transplantation in the management for
hepatocellular carcinoma is well defined, to date, there has been no report on its treatment value for
cHCC-CC. We report our experience of orthotopic liver transplantation in three patients with cHCC-CC.
One patient succumbed to distant metastases 16.5 months after liver transplantation whereas the other
two patients continued to survive 35 and 25 months after transplantation, respectively. [Asian J Surg
2007;30(2):143–6]
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Introduction
Combined hepatocellular cholangiocarcinoma (cHCC-CC)
is an uncommon but discrete variant of primary liver can-
cer. It accounts for 0.6–14% of all primary malignant liver
tumours.1–7 Histologically, the tumour demonstrates fea-
tures of both hepatocellular and biliary epithelial differ-
entiation. Hepatic resection remains the only curative
treatment option but the clinical outcome is disappoint-
ing with an overall median survival of 7.6–37 months
only. 2,5,7 The clinical outcome of orthotopic liver trans-
plantation in patients with hepatocellular carcinoma (HCC)
is well defined, but its role in the management of cHCC-CC
remains largely unknown. During the study period between
January 1994 and November 2005, 458 liver transplants
were performed in Queen Mary Hospital, The University
of Hong Kong, and we identified three patients with
cHCC-CC among all these patients. We hereby describe
our experience in the clinical management of these three
patients.
Case reports
Case 1
A 47-year-old male patient who was a known hepatitis B
carrier was found to have a liver mass on ultrasonography
during routine screening in 2002. Computed tomography
(CT) scan of the abdomen and hepatic angiogram con-
firmed a hypervascular solitary mass with a measurement
of 3 × 5 × 2.1 cm in segment V of the liver. Liver function
test revealed Child-Pugh Class C status. CT scan of the
thorax and bone scan confirmed no evidence of distant
metastasis. The clinical diagnosis at that time was HCC
in a markedly cirrhotic liver.
Deceased donor liver transplantation was subsequently
performed in July 2002. At laparotomy, a tumour about
5 cm in size was identified in segment V of the liver and 
a thrombus was found inside the main portal vein with
evidence of recannulation. The procedure was uneventful
and the patient was discharged home on day 15 after liver
transplantation. Tacrolimus 2 mg bid and mycophenolate
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mofetil 750 mg bid were prescribed for immunosuppres-
sion upon discharge.
Histological examination of the tumour revealed a
moderately-differentiated HCC with tumour cells arranged
in nodules with trabecular and pseudoglandular patterns.
Clusters of low cuboidal tumour cells in glandular arrange-
ment were also identified within the tumour. Microsatellite
lesions were present and tumour infiltration into the bile
duct and veins was also seen. Macroscopically, the tumour
was a well-circumscribed lesion measuring 9 × 6 × 6 cm.
There was no evidence of nodal involvement or distant
metastasis. The tumour was classified as T3N0M0 disease
(stage IIIa).8
He remained disease-free until 4 months after liver
transplantation when a metastatic right lung lesion was
identified on CT scan. Serum α-fetoprotein was elevated
from 10 ng/mL to 76 ng/mL at that time. Video-assisted
thoracoscopic resection of the right lung lesion was sub-
sequently performed. Unfortunately, there was disease
progression and follow-up CT scan at 5 months after lung
resection revealed increasing number and size of pul-
monary metastasis. Furthermore, bony metastasis to the
left humerus was identified on bone scan which required
prophylactic intramedullary nailing to avoid pathological
fracture. The condition of this patient further deterio-
rated and he finally succumbed 16.5 months after liver
transplantation.
Case 2
A 49-year-old male patient who was a known hepatitis B
carrier was diagnosed to have HCC in 1998 which was then
surgically resected. Histological examination of the tumour
revealed a well-encapsulated, moderately-differentiated
HCC with a microtrabecular pattern and extensive necro-
sis. There was no feature of venous permeation or micro-
satellite lesion. No bile duct proliferation was identified
and the resection margin was clear. However, tumour
recurrence at segment VII was detected on surveillance CT
scan at about 4 years after initial hepatic resection. In view
of the unsatisfactory liver function (Child-Pugh class C), the
tumour was deemed inoperable. Two courses of transarte-
rial oily chemoembolization were subsequently given but the
tumour remained unchanged in size after treatment. In view
of the underlying poor liver function and the small sized
tumour, liver transplantation was offered to this patient.
Live donor liver transplantation was performed in
December 2002. Laparotomy revealed a tumour with 
ill-defined margin in segment VIII of the liver. Macroscopi-
cally, the tumour was firm and tan-coloured with a meas-
urement of 5.8 × 2.0 × 2.0 cm. Histological examination of
the tumour revealed a moderately-differentiated cHCC-CC
with uncapsulated and infiltrative borders. Several satellite
nodules were present but there was no evidence of lym-
phovascular permeation. The tumour was classified as
T2N0M0 disease (stage II).8
This patient was discharged on postoperative day 12 and
tacrolimus was given for immunosuppression. His liver
function remained satisfactory and serum α-fetoprotein
level was all along within normal range (< 20 ng/mL). He
remained alive with no evidence of tumour recurrence at
35 months after liver transplantation.
Case 3
A 59-year-old female patient with history of chronic hep-
atitis B infection received live donor liver transplantation
in October 2003. The indication was poor liver function
(Child-Pugh class C) complicated by refractory hydrotho-
rax and ascites. Preoperative CT scan of the abdomen
revealed a very cirrhotic liver with no evidence of liver
malignancy. Laparotomy revealed a markedly cirrhotic
liver with 1 L of clear ascitic fluid within the peritoneal cav-
ity. There were features of severe portal hypertension with
an enlarged spleen four times larger than its normal size.
Histological examination of the native liver revealed active
cirrhosis with regeneration nodules. A small cHCC-CC
about 12 mm in diameter was incidentally found in one
section of the native liver. The hepatocytes within this
lesion demonstrated moderate pleomorphism with thick-
ened trabeculae and conspicuous bile production. The
bile ductules adjacent to this lesion also demonstrated
pleomorphism with prominent nucleoli. No feature of
lymphovascular permeation was noted. The tumour was
classified as T1N0M0 disease (stage I).8
The patient was discharged on postoperative day 23 with
tacrolimus given for immunosuppression. She remained
alive with no evidence of tumour recurrence at 25 months
after liver transplantation.
Discussion
cHCC-CC is an uncommon but a distinctive variant 
of HCC and cholangiocarcinoma (CC) with respect to 
its histological changes and prognosis. Histologically,
Goodman et al1 categorized the tumour into three 
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types: (i) collision type; (ii) transitional type and (iii) fibro-
lamellar type. Diagnosis of cHCC-CC is based on the pres-
ence of dual differentiation of hepatocellular and biliary
epithelial cells. Demonstration of mucin production is
essential to confirm the cholangiocellular component of
the tumour. However, in cases where mucin production 
is absent but a high suspicion of cholangiocellular com-
ponent of the tumour is present, the use of electron
microscopy to reveal biliary differentiation could be useful
to confirm the diagnosis.5
It has been suggested that cHCC-CC is associated with
a higher resectability rate when compared with HCC owing
to the lower prevalence of positive hepatitis B serology
and liver cirrhosis in cHCC-CC patients.3 However, such
claims have to be considered with caution as the preva-
lence of viral hepatitis is different between Western and
Eastern countries. Koh et al2 reported in their recent
series that over 50% of the patients with mixed HCC-CC
were chronic hepatitis B carriers, and up to 10% of the
patients were anti-HCV positive. In contrast, Jarnagin et al3
reported that merely 15% of the patients with cHCC-CC
were either HBsAg or anti-HCV positive. Furthermore,
Takguchi et al9 reported that 40% of the patients with
cHCC-CC were also cirrhotic with a positive hepatitis
serology, whereas in Jarnagin et al’s series,3 only 13% of the
patients were cirrhotic. Such difference in the prevalence
of liver cirrhosis and positive serology for hepatitis B or C
virus could also explain the discrepancy in the histological
resemblance of cHCC-CC to either HCC or CC in various
series. Reports that were published from endemic areas 
of hepatitis B or C infection favoured cHCC-CC to be
more histologically alike to HCC than CC. In a series 
of 26 patients with cHCC-CC, Yano et al4 reported that
this tumour showed great similarity to HCC in terms 
of male/female ratio, prevalence of hepatitis infection, 
α-fetoprotein level and nontumourous liver histology. Koh
et al2 also reported that the prevalence of positive serology
for hepatitis B virus and cirrhosis was higher in cHCC-CC
patients than in CC patients, but lower than that in HCC
patients. In contrast, a molecular analysis study conducted
in France by Cazals-Hatem et al6 identified that similar
genetic alterations occurred more often between cHCC-CC
and CC patients, than between HCC-CC and HCC patients.
cHCC-CC follows an aggressive clinical course with a
median survival in the range of 10–52 months.2,10,11 Some
authors suggested that cHCC-CC has a better prognosis
than CC but worse than that of HCC.2,3 On the contrary,
our experience showed that the median disease-free sur-
vival was the worst among HCC and CC patients (cHCC-
CC: 10 months; HCC: 18 months; CC: 24 months).12 The
3-year and 5-year survival rates for resected cases are in the
range of 40–50%2,7,9,10 and 24–30%,7,10 respectively. For
unresectable cases, the prognosis worsened significantly
with 3-year and 5-year survival rates of only 15.1% and
5.9%, respectively.10 A number of histological features that
could affect the prognosis have been identified. Multiple
tumours, portal vein or hepatic vein invasion and lym-
phatic metastases were all associated with poor prognosis
in terms of tumour recurrence and overall survival.2,3
Some of these prognostic indicators (bile duct and venous
invasion) were also observed in our mortality case but not
in the other two survivors.
The role of orthotopic liver transplantation in 
the management of HCC is well defined but its role 
for cHCC-CC is largely unknown. It is not unlikely that
there could be cases of cHCC-CC in major series of 
liver transplantation for HCC but clear documentation 
of liver transplantation for cHCC-CC is lacking. In our
study, two out of three patients survived without tumour
recurrence at 35 and 25 months, respectively, after 
liver transplantation. Their survival surpassed those with
resectable7 and nonresectable10 cases. We therefore pro-
pose that liver transplantation may have a role in the
management of cHCC-CC. The data presented herein 
will allow pooling from future publications on similar
subjects.
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